CompanyGraphAt a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $141.81M, lower than 95% of all stocks globally
- PositionPrice-to-book is 0.66×, lower than 95% of its Biotechnology peers (median 2.86×)
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
141.81MUSDvs all stocks (USD)
Revenue (TTM)
35.84MUSDvs all stocks (USD)
Profit Margin
-184.15%vs Biotechnology peers
52-Week Change
-80.55%vs all stocks
Market Capitalization
141.81MUSDvs all stocks (USD)
Enterprise Value
-120.41MUSDvs all stocks (USD)
Forward P/E
-1.03xvs Biotechnology peers
Price to Sales (TTM)
3.96xvs Biotechnology peers
Price to Book (MRQ)
0.6609xvs Biotechnology peers
Enterprise to Revenue
-3.36xvs Biotechnology peers
Enterprise to EBITDA
1.76xvs Biotechnology peers
Profit Margin
-184.15%vs Biotechnology peers
Operating Margin
-752.93%vs Biotechnology peers
Return on Assets (TTM)
-27.55%vs Biotechnology peers
Return on Equity (TTM)
-36.99%vs Biotechnology peers
Revenue (TTM)
35.84MUSDvs all stocks (USD)
Revenue per Share (TTM)
2.10USDUpdated Sep 28, 2026Quarterly Revenue Growth
-21.90%vs Biotechnology peers
Gross Profit (TTM)
-20.20MUSDvs all stocks (USD)
EBITDA (TTM)
-68.53MUSDvs all stocks (USD)
Net Income (TTM)
-65.99MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-53.19MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-76.68MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
18.62MUSDFY2025 · Dec 31, 2025Operating Income
-76.81MUSDvs all stocks (USD)
Pre-tax Income
-76.83MUSDFY2025 · Dec 31, 2025Income Tax Expense
-142.00KUSDFY2025 · Dec 31, 2025Net Income
-76.68MUSDFY2025 · Dec 31, 2025EBIT
-76.81MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-76.49MUSDFY2025 · Dec 31, 2025Research & Development
53.76MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
41.68MUSDFY2025 · Dec 31, 2025EPS (Basic)
-4.48USDFY2025 · Dec 31, 2025EPS (Diluted)
-4.48USDFY2025 · Dec 31, 2025Basic Shares Outstanding
17.11MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
17.11MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-49.50MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-50.67MUSDFY2025 · Dec 31, 2025Free Cash Flow
-52.11MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
0.00USDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-49.50MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
323.00KUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
-142.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
7.68MUSDFY2025 · Dec 31, 2025Other Non-cash Items
572.00KUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
0.00USDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
3.73MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-13.33MUSDFY2025 · Dec 31, 2025Capital Expenditures
-1.45MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-1.45MUSDFY2025 · Dec 31, 2025Other Financing Charges
42.57MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
42.57MUSDFY2025 · Dec 31, 2025Shares Outstanding
17.11MSharesUpdated Sep 28, 2026Float Shares
15.04MSharesUpdated Sep 28, 2026Shares Short
3.35MSharesUpdated Sep 28, 2026Short Ratio
11.64daysvs all stocks
% Held by Insiders
4.16%vs all stocks
% Held by Institutions
84.46%vs all stocks
Total Cash (MRQ)
263.90MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
15.43USDUpdated Sep 28, 2026Total Debt (MRQ)
1.68MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0078xvs Biotechnology peers
Current Ratio (MRQ)
8.73xvs Biotechnology peers
Book Value per Share (MRQ)
12.54USDUpdated Sep 28, 2026Total Assets
278.35MUSDvs all stocks (USD)
Total Current Assets
272.85MUSDFY2025 · Dec 31, 2025Total Liabilities
71.07MUSDFY2025 · Dec 31, 2025Total Non-current Assets
5.51MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
29.27MUSDFY2025 · Dec 31, 2025Total Current Liabilities
41.80MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
270.00MUSDFY2025 · Dec 31, 2025Accounts Payable
4.40MUSDFY2025 · Dec 31, 2025Short-term Debt
3.67MUSDFY2025 · Dec 31, 2025Deferred Revenue
21.64MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
574.00KUSDFY2025 · Dec 31, 2025Common Stock (Book)
17.00KUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
207.29MUSDvs all stocks (USD)
52-Week Low
8.10USDUpdated Sep 28, 202652-Week High
73.06USDUpdated Sep 28, 202652-Week Change
-80.55%vs all stocks
50-Day MA
11.78USDUpdated Sep 28, 2026200-Day MA
12.76USDUpdated Sep 28, 2026Avg 10-Day Volume
422.60KSharesUpdated Sep 28, 2026Avg 30-Day Volume
333.21KSharesUpdated Sep 28, 2026Diluted EPS (TTM)
-5.44USDUpdated Sep 28, 2026Other Income / Expense
-12.00KUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Price-to-book is 0.66×, lower than 95% of its Biotechnology peers (median 2.86×)Notable
Price-to-book: 0.66Industry median: 2.86Industry P5: 0.98Peers compared: 260
Financial Health
Altman Z-Score 1.35: grey zoneSignificant
Altman Z-Score: 1.35
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $141.81M, lower than 95% of all stocks globallySignificant
Market cap (USD): 141,805,780Global P5: 275,556,405.438
Companies that share the same coordination system — how they create, deliver, or capture value.
Futurechem Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Scancell Holdings Plc
Tier 1ProductionApproval-Gated PipelineRuleRisk
Curacle Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Enlivex Therapeutics Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Yungjin Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
HLB Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
EKF Diagnostics Holdings plc
Tier 1ProductionApproval-Gated PipelineRuleFlow
S Biomedics Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Chill Brands Group Plc
Tier 1ProductionApproval-Gated PipelineRuleFlow
Pyridam Farma Tbk.
Tier 1ProductionApproval-Gated PipelineRuleFlow